Global Antibody-oligonucleotide Conjugates (AOCs) Market Size, Status and Forecast 2026-2032

Antibody-oligonucleotide Conjugates (AOCs) Market

AOCs (Antibody-Oligonucleotide Conjugates) consist of three main components: a carrier (antibody), a linker, and a small nucleic acid. They allow for targeted delivery, combining the antibody’s ability to bind to specific cells with the gene-silencing capability of small nucleic acids, addressing the delivery challenges faced by conventional small nucleic acid drugs.

The development of Antibody-Oligonucleotide Conjugates (AOCs) aims to address the inherent limitations of small nucleic acids, such as poor serum stability, low membrane permeability, and lack of tissue selectivity. AOCs combine the longer half-life and precise targeting capabilities of antibodies with the gene-silencing power of small nucleic acids, achieving high-precision selectivity and effective delivery to target cells.

The global Antibody-oligonucleotide Conjugates (AOCs) market is experiencing explosive growth, with the core driving force coming from clinical breakthroughs in rare diseases (such as Duchenne muscular dystrophy and myotonic dystrophy) and innovative needs for targeted tumor therapy. Leading companies Avidity Biosciences (AOC 1001 clinical phase II) and Dyne Therapeutics (FORCE™ platform) are leading the race. On the technical side, pH-sensitive linkers optimize oligonucleotide release and bispecific antibody design improves tissue penetration, but low lysosomal escape efficiency (<10%) and high large-scale production costs (single dose exceeds US$50,000) are still the main bottlenecks. Regionally, North America accounts for more than 60% of the market share thanks to FDA accelerated approval and biotechnology clusters, while Asia Pacific relies on CDMO companies such as WuXi Biologics to enter the production link. In the next 3-5 years, with more than 20 AOC pipelines entering the clinic (indications expanding to ophthalmology and CNS) and AI-driven conjugation design (such as generative AI-optimized antibody-oligonucleotide pairing) being implemented, this field is expected to replicate the successful path of ADC drugs and become the next tens of billions of dollars market for precision medicine.

This report focuses on the global Antibody-oligonucleotide Conjugates (AOCs) status, future forecast, growth opportunity, key market, and key players. The study objectives are to present the Antibody-oligonucleotide Conjugates (AOCs) development in different regions.

It segments the global Antibody-oligonucleotide Conjugates (AOCs) market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Antibody-oligonucleotide Conjugates (AOCs) manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Antibody-oligonucleotide Conjugates (AOCs) Market Report

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Type (2026-2032)

1.2.2 Site-specific Coupling

1.2.3 Random Coupling

1.3 Market by Application

1.3.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2026-2032)

1.3.2 Rare and Genetic Diseases

1.3.3 Cancer Treatment

1.3.4 Central Nervous System Disorders

1.4 Study Objectives

1.5 Years Considered

2.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size

2.2 Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region

2.2.1 Antibody-oligonucleotide Conjugates (AOCs) Growth Rate by Region (2026-2032)

2.2.2 Antibody-oligonucleotide Conjugates (AOCs) Market Share by Region (2026-2032)

2.3 Industry Trends

2.3.1 Market Top Trends

2.3.2 Market Use Cases

3.1 Antibody-oligonucleotide Conjugates (AOCs) Revenue by Players (2026 & 2032)

3.2 Antibody-oligonucleotide Conjugates (AOCs) Key Players Headquarters and Area Served

3.3 Key Players Antibody-oligonucleotide Conjugates (AOCs) Product/Solution/Service

3.4 Date of Enter into Antibody-oligonucleotide Conjugates (AOCs) Market

3.5 Mergers & Acquisitions, Expansion Plans

4.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2032)

4.2 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2032)

5.1 North America Antibody-oligonucleotide Conjugates (AOCs) Market Forecast (2026-2032)

5.2 Antibody-oligonucleotide Conjugates (AOCs) Key Players in North America

5.3 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type

5.4 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application

6.1 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Forecast (2026-2032)

6.2 Antibody-oligonucleotide Conjugates (AOCs) Key Players in Europe

6.3 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type

6.4 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application

7.1 China Antibody-oligonucleotide Conjugates (AOCs) Market Forecast (2026-2032)

7.2 Antibody-oligonucleotide Conjugates (AOCs) Key Players in China

7.3 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type

7.4 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application

8.1 Japan

8.1.1 Japan Antibody-oligonucleotide Conjugates (AOCs) Market Analysis

8.1.2 Key Players in Japan

9.1 Avidity Biosciences

9.1.1 Avidity Biosciences Company Details

9.1.2 Avidity Biosciences Description and Business Overview

9.1.3 Avidity Biosciences Antibody-oligonucleotide Conjugates (AOCs) Introduction

9.1.4 Avidity Biosciences Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2026 & 2032)

9.1.5 Avidity Biosciences Recent Development

9.2 Dyne Therapeutics

9.2.1 Dyne Therapeutics Company Details

9.2.2 Dyne Therapeutics Description and Business Overview

9.2.3 Dyne Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Introduction

9.2.4 Dyne Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2026 & 2032)

9.2.5 Dyne Therapeutics Recent Development

9.3 Tallac Therapeutics

9.3.1 Tallac Therapeutics Company Details

9.3.2 Tallac Therapeutics Description and Business Overview

9.3.3 Tallac Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Introduction

9.3.4 Tallac Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2026 & 2032)

9.3.5 Tallac Therapeutics Recent Development

9.4 Denali Therapeutics

9.4.1 Denali Therapeutics Company Details

9.4.2 Denali Therapeutics Description and Business Overview

9.4.3 Denali Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Introduction

9.4.4 Denali Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2026 & 2032)

9.4.5 Denali Therapeutics Recent Development

9.5 Gennao Bio

9.5.1 Gennao Bio Company Details

9.5.2 Gennao Bio Description and Business Overview

9.5.3 Gennao Bio Antibody-oligonucleotide Conjugates (AOCs) Introduction

9.5.4 Gennao Bio Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2026 & 2032)

9.5.5 Gennao Bio Recent Development

9.6 ChainGen Bio

9.6.1 ChainGen Bio Company Details

9.6.2 ChainGen Bio Description and Business Overview

9.6.3 ChainGen Bio Antibody-oligonucleotide Conjugates (AOCs) Introduction

9.6.4 ChainGen Bio Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2026 & 2032)

9.6.5 ChainGen Bio Recent Development

10.1 Antibody-oligonucleotide Conjugates (AOCs) Industry Trends

10.2 Antibody-oligonucleotide Conjugates (AOCs) Market Drivers

10.3 Antibody-oligonucleotide Conjugates (AOCs) Market Challenges

10.4 Antibody-oligonucleotide Conjugates (AOCs) Market Restraints

12.1 Research Methodology

12.1.1 Methodology/Research Approach

12.1.1.1 Research Programs/Design

12.1.1.2 Market Size Estimation

12.1.1.3 Market Breakdown and Data Triangulation

12.1.2 Data Source

12.1.2.1 Secondary Sources

12.1.2.2 Primary Sources

12.2 Disclaimer

12.3 Author Details

List of Tables

 Table 1. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Type (2026-2032) & (US$ Million)

 Table 2. Key Players of Site-specific Coupling

 Table 3. Key Players of Random Coupling

 Table 4. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth by Application (2026-2032) & (US$ Million)

 Table 5. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2026-2032) & (US$ Million)

 Table 6. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2026-2032) & (US$ Million)

 Table 7. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Region (2026-2032)

 Table 8. Market Top Trends

 Table 9. Market Use Cases

 Table 10. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue by Players (2026 & 2032) & (US$ Million)

 Table 11. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Players (2026 & 2032)

 Table 12. Key Players Headquarters and Area Served

 Table 13. Key Players Antibody-oligonucleotide Conjugates (AOCs) Product/Solution/Service

 Table 14. Date of Enter into Antibody-oligonucleotide Conjugates (AOCs) Market

 Table 15. Mergers & Acquisitions, Expansion Plans

 Table 16. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2032) & (US$ Million)

 Table 17. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Share by Type (2026-2032)

 Table 18. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2032) & (US$ Million)

 Table 19. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Share by Application (2026-2032)

 Table 20. North America Key Players Antibody-oligonucleotide Conjugates (AOCs) Revenue (2026 & 2032) & (US$ Million)

 Table 21. North America Key Players Antibody-oligonucleotide Conjugates (AOCs) Market Share (2026 & 2032)

 Table 22. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2032) & (US$ Million)

 Table 23. North America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2026-2032)

 Table 24. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2032) & (US$ Million)

 Table 25. North America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2026-2032)

 Table 26. Europe Key Players Antibody-oligonucleotide Conjugates (AOCs) Revenue (2026 & 2032) & (US$ Million)

 Table 27. Europe Key Players Antibody-oligonucleotide Conjugates (AOCs) Market Share (2026 & 2032)

 Table 28. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2032) & (US$ Million)

 Table 29. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2026-2032)

 Table 30. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2032) & (US$ Million)

 Table 31. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2026-2032)

 Table 32. China Key Players Antibody-oligonucleotide Conjugates (AOCs) Revenue (2026 & 2032) & (US$ Million)

 Table 33. China Key Players Antibody-oligonucleotide Conjugates (AOCs) Market Share (2026 & 2032)

 Table 34. China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2032) & (US$ Million)

 Table 35. China Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2026-2032)

 Table 36. China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2032) & (US$ Million)

 Table 37. China Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2026-2032)

 Table 38. Key Players in Japan

 Table 39. Avidity Biosciences Company Details

 Table 40. Avidity Biosciences Description and Business Overview

 Table 41. Avidity Biosciences Antibody-oligonucleotide Conjugates (AOCs) Product

 Table 42. Avidity Biosciences Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business: 2026 & 2032

 Table 43. Avidity Biosciences Recent Development

 Table 44. Dyne Therapeutics Company Details

 Table 45. Dyne Therapeutics Description and Business Overview

 Table 46. Dyne Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product

 Table 47. Dyne Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business: 2026 & 2032

 Table 48. Dyne Therapeutics Recent Development

 Table 49. Tallac Therapeutics Company Details

 Table 50. Tallac Therapeutics Description and Business Overview

 Table 51. Tallac Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product

 Table 52. Tallac Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business: 2026 & 2032

 Table 53. Tallac Therapeutics Recent Development

 Table 54. Denali Therapeutics Company Details

 Table 55. Denali Therapeutics Description and Business Overview

 Table 56. Denali Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product

 Table 57. Denali Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business: 2026 & 2032

 Table 58. Denali Therapeutics Recent Development

 Table 59. Gennao Bio Company Details

 Table 60. Gennao Bio Description and Business Overview

 Table 61. Gennao Bio Antibody-oligonucleotide Conjugates (AOCs) Product

 Table 62. Gennao Bio Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business: 2026 & 2032

 Table 63. Gennao Bio Recent Development

 Table 64. ChainGen Bio Company Details

 Table 65. ChainGen Bio Description and Business Overview

 Table 66. ChainGen Bio Antibody-oligonucleotide Conjugates (AOCs) Product

 Table 67. ChainGen Bio Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business: 2026 & 2032

 Table 68. ChainGen Bio Recent Development

 Table 69. Antibody-oligonucleotide Conjugates (AOCs) Market Trends

 Table 70. Antibody-oligonucleotide Conjugates (AOCs) Market Drivers

 Table 71. Antibody-oligonucleotide Conjugates (AOCs) Market Challenges

 Table 72. Antibody-oligonucleotide Conjugates (AOCs) Market Restraints

 Table 73. Research Programs/Design for This Report

 Table 74. Key Data Information from Secondary Sources

 Table 75. Key Data Information from Primary Sources

List of Figures

 Figure 1. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type in 2026 & 2032

 Figure 2. Site-specific Coupling Features

 Figure 3. Random Coupling Features

 Figure 4. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application in 2026 & 2032

 Figure 5. Rare and Genetic Diseases Case Studies

 Figure 6. Cancer Treatment Case Studies

 Figure 7. Central Nervous System Disorders Case Studies

 Figure 8. Antibody-oligonucleotide Conjugates (AOCs) Report Years Considered

 Figure 9. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size and Growth Rate 2026-2032 (US$ Million)

 Figure 10. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Region (2026-2032)

 Figure 11. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Market Share by Type (2026-2032)

 Figure 12. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size 2026-2032 (US$ Million)

 Figure 13. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size 2026-2032 (US$ Million)

 Figure 14. China Antibody-oligonucleotide Conjugates (AOCs) Market Size 2026-2032 (US$ Million)

 Figure 15. Antibody-oligonucleotide Conjugates (AOCs) Market Size in Japan (2026-2032) & (US$ Million)

 Figure 16. Bottom-up and Top-down Approaches for This Report

 Figure 17. Data Triangulation

 Figure 18. Key Executives Interviewed